IMGN - Goldman starts ImmunoGen at neutral cites valuation
2023-11-20 16:28:23 ET
More on ImmunoGen
- ImmunoGen, Inc. (IMGN) Q3 2023 Earnings Call Transcript
- Analyzing The Acquisition Potential Of ImmunoGen
- ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?
- ImmunoGen stock gains 7% amid Q3 report, positive study results
- ImmunoGen Q3 2023 Earnings Preview
For further details see:
Goldman starts ImmunoGen at neutral, cites valuation